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Evidence for disturbed insulin and growth hormone signaling
as potential risk factors in the development of schizophrenia
NJM van Beveren1,2,3,7, E Schwarz4,7, R Noll5, PC Guest4, C Meijer6, L de Haan6 and S Bahn1,4
Molecular abnormalities in metabolic, hormonal and immune pathways are present in peripheral body ﬂuids of a signiﬁcant
subgroup of schizophrenia patients. The authors have tested whether such disturbances also occur in psychiatrically ill and
unaffected siblings of schizophrenia patients with the aim of identifying potential contributing factors to disease vulnerability. The
subjects were recruited as part of the Genetic Risk and OUtcome of Psychosis (GROUP) study. The authors used multiplexed
immunoassays to measure the levels of 184 molecules in serum from 112 schizophrenia patients, 133 siblings and 87 unrelated
controls. Consistent with the ﬁndings of previous studies, serum from schizophrenia patients contained higher levels of insulin,
C-peptide and proinsulin, decreased levels of growth hormone and altered concentrations of molecules involved in inﬂammation.
In addition, signiﬁcant differences were found in the levels of some of these proteins in siblings diagnosed with mood disorders
(n= 16) and in unaffected siblings (n= 117). Most signiﬁcantly, the insulin/growth hormone ratio was higher across all groups
compared with the controls. Taken together, these ﬁndings suggest the presence of a molecular endophenotype involving
disruption of insulin and growth factor signaling pathways as an increased risk factor for schizophrenia.
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INTRODUCTION
Recent investigations have led to identiﬁcation of abnormal
molecular proﬁles in blood serum and plasma of schizophrenia
patients.1–12 Many of these studies have found changes in
molecules linked to insulin resistance and glucose handling in
schizophrenia patients, including patients who have not received
antipsychotic medications.1,13,14 The affected molecules include
neuroendocrine hormones such as insulin, prolactin, pancreatic
polypeptide, chromogranin A and growth hormone.4,5,8 Although
such effects have been associated previously with response to
antipsychotic treatment, potential links between schizophrenia
and type 2 diabetes mellitus have been reported for 450 years,
even before the development of antipsychotics. Such effects on
insulin signaling are consistent with the ﬁndings of proteomic
proﬁling analyses, which showed disrupted altered metabolic
protein levels in postmortem brain tissues from schizophrenia
patients.15–17
The question of whether these changes are a cause or effect of
schizophrenia has not been answered. One approach to resolve
this issue is to investigate unaffected relatives of patients.
Abnormalities found in siblings of schizophrenia patients may
provide clues to the cause of the illness, especially regarding the
existence of predisposing factors.18 It has been established that
genetic factors contribute to the development of schizophrenia as
monozygotic twins show a 40–80% concordance rate and siblings
of patients have an approximate 10-fold increased risk for
psychosis.19,20 Also, studies have shown that some unaffected
relatives of schizophrenia patients exhibit abnormalities in
electrophysiological, neurocognitive, symptomatic and behavioral
abnormalities found in some psychiatric conditions.21 One small
study had reported abnormal glucose responses after oral glucose
tolerance tests in six siblings of schizophrenia patients, providing
some evidence that supports an association between family-risk
for schizophrenia and metabolic disorders.22
Here, we have investigated whether common disturbances in
molecular pathways could be identiﬁed in the serum from
patients and their siblings as potential risk factors for develop-
ment of schizophrenia. Blood serum samples from all subjects
were analyzed by multiplex immunoassays and the resulting
molecular ﬁngerprints compared among schizophrenia patients,
their siblings and unrelated controls.
MATERIALS AND METHODS
Subjects
The subjects were a subset of the large Dutch ‘Genetic Risk and OUtcome
in Psychosis’ (GROUP) project23 and consisted of 112 patients, 133 siblings
and 87 controls. For the current study, patients were selected with a
diagnosis of schizophrenia, schizophreniform or schizoaffective disorder
(hereafter referred to as schizophrenia) and were matched closely for age
and body mass index (Table 1). Diagnosis was based on Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) criteria and symptom
severity was assessed with the Positive and Negative Syndrome Scale.24
The possible presence of subclinical psychosis in asymptomatic siblings
and healthy controls was assessed with the Community Assessment of
Psychic Experiences.25 Of the siblings, 16 had a DSM-IV diagnosis
(symptomatic) and 117 did not (asymptomatic). The presence of
psychiatric disorders in 12% of the siblings was consistent with the
presence of predisposing factors for mental illness. Control subjects had no
ﬁrst- or second-degree siblings with a psychotic disorder and were also
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matched closely for age and body mass index. The local ethical
committees approved the protocols of the study. The study was conducted
according to the Declaration of Helsinki and written informed consent was
obtained after complete description of the study to the subjects.
Multiplex immunoassay
Blood samples were obtained from all patients as available and were not
necessarily collected under fasting conditions. Serum was prepared and
analyzed using the Human DiscoveryMAP (Myriad RBM, Austin, TX, USA)
multiplexed immunoassay platform, which measures the concentrations of
184 proteins and small molecules (Supplementary Table 1), as described
previously.9 For each measured serum protein, values measured below the
lower limit of detection were replaced by half the lowest concentration
determined for the respective analyte. Variation in protein levels were
investigated using linear mixed-effects models with regard to established
diagnosis, presence of symptoms and family membership. Potential
covariates such as age, gender and body mass index were included in
the models. For proteins with nonsigniﬁcant diagnosis–covariate interac-
tions, additive models were compared against reduced models without
diagnosis information to obtain adjusted P-values. Otherwise, diagnosis
main effect P-values are shown. All P-values were corrected for multiple
hypotheses testing by controlling the false-discovery rate (Q-values), and
ﬁndings of Po0.05 and Qo0.1 were designated as signiﬁcant.
RESULTS
Schizophrenia patients
Multiplex immunoassay analysis showed that 10 proteins were
present at signiﬁcantly different levels between schizophrenia
patients and controls (Table 2). The changes in proinsulin, insulin
and C-peptide provide some validation of the ﬁndings due to the
precursor product relationship of these proteins.26 Also, the levels
of insulin and C-peptide showed a signiﬁcant correlation (Pearson;
r= 0.89; Po0.001). These changes in the insulin-related peptides
are consistent with those of a previous study using single-plex
immunoassays, which found similar results in 66 ﬁrst-onset
schizophrenia patients compared with 68 controls.5 The additional
ﬁnding of reduced growth hormone levels suggests that both
metabolism and growth signaling pathways may be altered in
schizophrenia patients. Similar changes in these hormones were
also found in a multiplex immunoassay study of 250 ﬁrst-onset
schizophrenia patients compared with 230 controls.9 In line with
other studies on schizophrenia patients, most of the remaining
proteins had functions associated with the inﬂammatory response,
such as T-lymphocyte-secreted protein I 309, CD5L, interferon-γ-
induced protein 10, immunoglobulin M and chromogranin A.3,4,9
However, we did not ﬁnd signiﬁcant differences in the levels of
other molecules such as cortisol and haptoglobin, which have
been found consistently to be altered in other studies of ﬁrst-
onset antipsychotic-naive schizophrenia patients.
Siblings
Of 10 altered proteins in schizophrenia patients, 5 of these
showed signiﬁcant differences in symptomatic siblings and 5 were
also altered in asymptomatic siblings (Table 2). Four proteins
(insulin, C-peptide, T-lymphocyte-secreted protein I 309 and
growth hormone) were signiﬁcantly altered in both symptomatic
and asymptomatic siblings. Interestingly, insulin was consistently
increased and growth hormone decreased in patients and both
sibling groups compared with controls. Likewise, the insulin/
growth hormone ratio was increased in patients (ratio = 2.2;
Po0.001), symptomatic siblings (ratio = 1.9; P= 0.0214) and
asymptomatic siblings (ratio = 1.4; P= 0.0021) compared with
controls (Figure 1). We next determined the proportion of subjects
in each group that had high insulin/growth hormone ratios in
schizophrenia patients and siblings compared with controls.
Insulin/growth hormone values were dichotomized such that
patients below the median (9.8 μIU ng− 1) were partitioned into
low group and those above the median were assigned to the high
group. This showed that the highest proportion of subjects with
high insulin/growth hormone values were found in the schizo-
phrenia patient group (67%), followed by the symptomatic
siblings (45%) and the asymptomatic siblings (43%) (Figure 2).
The controls had a signiﬁcantly lower proportion of high insulin/
growth hormone values (30%; Po0.001).
DISCUSSION
The changes in the insulin-related molecules are consistent with
other studies that have implicated glycoregulatory abnormalities
in schizophrenia, including impaired fasting glucose tolerance,
hyperinsulinemia and insulin resistance.1,5,8,13,15 A potential
linkage of these peripheral changes to alterations in brain
function have been suggested by 1H nuclear magnetic resonance
spectroscopy proﬁling studies that found decreased lactate and
increased glucose in cerebrospinal ﬂuid from ﬁrst-onset patients
compared with controls.27 Proteomic studies have also found
metabolic abnormalities in postmortem brain tissues from
schizophrenia patients.15,16,28 Furthermore, brain imaging studies
have established that reduced glucose uptake occurs in frontal
cortices of some patients with schizophrenia.29 Metabolic
perturbations have also been identiﬁed in the central nervous
system and periphery of bipolar disorder, major depressive
disorder and Alzheimer’s disease patients, suggesting that similar
effects may occur in other psychiatric disorders.
The most notable result of the current study was the ﬁnding
that altered levels of insulin and growth hormone in schizophrenia
patients were also present in siblings with and without a diagnosis
of psychiatric disorders. The increase in the insulin/growth
hormone ratio would be expected to cause a marked shift in
metabolic and growth-regulation pathways. These two hormones
can have counteractive effects on some tissues and striking
similarities exist between insulin resistance and growth hormone-
deﬁcient syndromes.30 Previous studies have shown that subjects
with growth hormone deﬁciency are insulin resistant,31 and long-
term growth hormone treatment of adults with a deﬁciency in this
Table 1. Demographic and clinical characteristics of patients, siblings
and healthy controls
SZ SS AS Controls
Number 112 16 117 87
Gender (male/female)a 97/15* 5/11* 57/60* 59/28
Ageb 24.5± 5.3 25.9± 7.6 27.1± 8.2 26.5± 9.6
Boddy mass index
(kgm−2)b
23.9± 3.6* 22.6± 3.4 22.9± 3.4 22.3± 3.0
PANSS
Positive 11.7± 5.2 — — —
Negative 14.7± 6.6 — — —
General 26.8± 8.8 — — —
Total 52.9± 17.5 — — —
Diagnosis
Schizophrenia and
schizophreniform
93 — —
Schizoaffective 19 — —
Eating disorder 1 — —
Depressive disorder 13 — —
Pervasive
developmental
disorder
2 — —
Abbreviations: AS, asymptomatic siblings; PANSS, positive and negative
syndrome scale; SS, symptomatic siblings; SZ, schizophrenia. aChi-square
test (*Po0.05 compared against controls). bWilcoxon rank sum test
(*Po0.05 compared against controls).
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hormone have been shown to improve insulin sensitivity and
whole-body glucose metabolism.32 In addition, the results of an
early study suggested that the reduced growth hormone levels
may be due to schizophrenia-associated increases in dopamine or
serotonin activities, which regulate the production of this
hormone.33 This is intriguing considering established hypotheses
for schizophrenia that have suggested a causal link to increased
levels of these neurotransmitters.34 We also found changes in the
levels of T-lymphocyte-secreted protein I 309 in all subjects
compared with controls, consistent with the effects on immune
system dysfunction, which are also observed in schizophrenia9
and metabolic syndrome.35
There are several limitations to consider in this analysis. First,
signiﬁcant differences were not found in the levels of molecules
such as cortisol and haptoglobin, which were described in other
studies of ﬁrst-onset antipsychotic-naive schizophrenia patients.9
However, this may be related to the clinical characteristics of the
current patients who were all medicated compared with the
antipsychotic-naive ﬁrst-episode patients analyzed previously.
Second, it was not possible to measure insulin resistance directly
in this study as blood glucose levels were not determined. This is
due to the fact that the samples were collected from patients and
controls as they became available, and were not necessarily
obtained under fasting conditions. Therefore, the measurements
used in the current study only give indirect readings and
represent approximations of insulin signaling. Third, no conclusion
can be drawn about the similarity of the insulin/growth hormone
ratios in the symptomatic (n= 16) and the asymptomatic sibling
(n= 117) groups, considering the small sample size of the former.
Finally, no records were obtained for any of the subjects under
study concerning family histories for occurrence of metabolic
conditions such as type 2 diabetes mellitus or metabolic
syndrome. This could be informative in future studies concerning
the known link between psychiatric disorders and metabolic
diseases, as revealed by proteomic and metabolomic studies.36–42
Overall, the present ﬁndings suggest that metabolic and
hormonal disturbances such as effects on insulin and growth
hormone may represent a vulnerability factor to develop mental
disorders. We hypothesize that genetically or environmentally
Table 2. Serum proteins altered between patients and siblings compared with controls
Analyte Patients vs controls Siblings vs controls
P Q Ratio Symptomatic Asymptomatic
P RC P RC
Insulin o0.001 o0.01 1.33 0.042 1.30 0.017 1.18
C-peptide o0.001 0.01 1.13 0.004 1.24 0.017 1.09
T-lymphocyte-secreted protein I 309 0.002 0.04 0.80 0.011 0.79 0.001 0.83
Growth hormone 0.006 0.08 0.58 0.006 0.65 0.032 0.81
Proinsulin 0.006 0.08 1.17 0.043 1.19 0.614 1.00
CD5L 0.002 0.04 0.95 0.207 0.95 0.035 0.96
Interferon-γ-induced protein 10 0.001 0.04 0.92 0.464 1.00 0.083 0.93
Immunoglobulin M 0.002 0.04 0.91 0.845 1.08 0.502 1.03
Carcinoembryonic antigen 0.005 0.07 1.17 0.667 0.98 0.959 0.97
Adiponectin 0.007 0.08 0.90 0.492 1.14 0.145 0.98
Abbreviation: RC, ratio vs controls. Serum samples from all subjects were analyzed by multiplex immunoassay analysis. All P-values were corrected for multiple
hypotheses testing by controlling the false-discovery rate (Q-values) and ﬁndings of Po0.05 and Qo0.1 were considered signiﬁcant (indicated in italics).
Analytes in bold were signiﬁcantly altered in patients as well as in both symptomatic and asymptomatic siblings.
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Figure 1. Boxplots showing altered levels of insulin and growth
hormone in schizophrenia patients and siblings compared with
controls. Serum concentrations of insulin (blue) and growth
hormone (GH, yellow) were determined using multiplexed immu-
noassays for control, asymptomatic siblings (AS), symptomatic
siblings (SS) and schizophrenia patients (SZ). The levels of insulin
in controls were 4.3± 5.0 μIU ml− 1 and those for growth hormone
were 3.7± 6.3 ngml− 1. All values were log10 transformed to
account for unequal distribution of the data. Bold horizontal bars
reﬂect median protein levels.
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Figure 2. Histograms showing higher insulin/growth hormone ratios
in schizophrenia patients and siblings compared with controls.
Proportion of patients with high (red) and low (black) insulin/growth
hormone ratios. The high and low categories were deﬁned as
subjects with higher and lower insulin:growth hormone ratios
compared with the median insulin:growth hormone ratio (9.8
μIU ng− 1), respectively.
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determined dysfunction in these pathways can result in deleter-
ious effects on the brain in predisposed individuals. For example,
intermittent glucose deprivation may occur in individuals with
sporadic neuronal hyperactivity and associated excessive brain
energy demand, which places stress on these pathways. This can
also occur in cases of neurodevelopmental deﬁcits affecting blood
supply to certain brain regions and peripheral inﬂammation that
deprives the body of glucose. Such effects may be correlated with
onset or the remitting relapsing course of psychiatric symptoms.
In this light, it is interesting that antipsychotic drugs are known to
increase peripheral glucose levels. Indeed, these pro-diabetic
effects are viewed as major side effects of these drugs. We
propose that these effects may be intrinsically related to the
therapeutic mechanism of action by increasing the peripheral
blood glucose levels and thereby increasing glucose availability in
the brain. Further research should attempt to disentangle the
contribution of environmental and genetic factors to the observed
molecular alterations. Furthermore, the production of tests based
on measurement of these molecules may allow identiﬁcation of
high-risk individuals. This could lead to the implementation of
novel disease prevention approaches, which could involve
nutrition modiﬁcation, stress reduction and pharmaco-
therapeutic interventions, including the application of well-
tolerated drugs that combat insulin resistance.
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